Sarcopenia is diagnosed through a stepwise process that evaluates muscle strength, muscle mass, and physical performance. The most widely used framework follows four stages: Find, Assess, Confirm, and determine Severity. This approach, developed by the European Working Group on Sarcopenia in Older People (EWGSOP2), gives clinicians a structured path from initial screening to a confirmed diagnosis with a severity rating.
The Four-Stage Diagnostic Pathway
The internationally recognized diagnostic algorithm uses the acronym F-A-C-S, and each stage builds on the last. You don’t need every test right away. The process starts broad and narrows down.
- Find: Screen for symptoms using a simple questionnaire or clinical suspicion.
- Assess: Test muscle strength with grip strength or a chair stand test.
- Confirm: Measure actual muscle quantity using a body composition scan.
- Severity: Evaluate how much the condition affects daily function through physical performance tests.
If the screening step raises concern, strength testing follows. Low strength alone qualifies as “probable sarcopenia” and is enough to start treatment. Confirmation through imaging solidifies the diagnosis, and performance testing tells you how advanced it is.
Step 1: Screening With the SARC-F
The first step is a five-question screening tool called the SARC-F. Each letter stands for something it asks about: Strength, Assistance walking, Rising from a chair, Climbing stairs, and Falls. You rate each item from 0 (no difficulty) to 2 (very difficult), giving a total score out of 10. A score of 4 or higher flags you as someone who should be evaluated further.
The SARC-F is intentionally simple. It requires no equipment and takes under a minute. Its strength is specificity: it rarely flags people who don’t have a problem. Its weakness is sensitivity, meaning it can miss milder cases. Some clinical guidelines, particularly those designed for Asian populations, add a calf circumference measurement to improve detection. In that version (called SARC-CalF), a score of 11 or higher triggers further testing, and calf circumference below 34 cm in men or 33 cm in women raises concern.
Step 2: Testing Muscle Strength
Once screening suggests a problem, the next step is measuring how strong your muscles actually are. Two tests dominate clinical practice: grip strength and the chair stand test.
Grip strength is measured with a handheld device called a dynamometer. You squeeze it as hard as you can, and the result is recorded in kilograms. The European consensus uses cut-off values of less than 27 kg for men and less than 16 kg for women to indicate low strength. Asian guidelines set slightly different thresholds: below 28 kg for men and below 18 kg for women, reflecting population-specific data. A recent 2025 study of older Chinese adults found optimal cut-offs of 29.6 kg for men and 20.3 kg for women, which shows these numbers continue to be refined.
The chair stand test is an alternative that works well when a dynamometer isn’t available. You cross your arms over your chest and stand up from a seated position five times as fast as you can. Taking 15 seconds or longer (12 seconds or longer under Asian guidelines) points to low muscle strength. This test is especially practical in community health settings because it needs no equipment at all.
If either test shows low strength, sarcopenia is considered “probable.” That’s clinically meaningful on its own, enough for a healthcare provider to recommend exercise and nutritional interventions while pursuing confirmation.
Step 3: Confirming With Muscle Mass Measurement
A confirmed diagnosis requires objective evidence that you have less muscle than expected for your body size. This is where body composition scanning comes in.
The gold standard in clinical practice is DXA (dual-energy X-ray absorptiometry), the same type of scan used for bone density testing. It measures lean tissue throughout your body, and the key number is your appendicular lean mass index (ALMI): the total lean mass in your arms and legs divided by your height squared. Low muscle mass is generally defined as an ALMI below approximately 7.0 kg/m² for men and below 5.4 to 6.0 kg/m² for women, though exact thresholds vary by guideline and reference population. The scan takes about 10 to 15 minutes, involves minimal radiation, and is widely available.
Bioelectrical impedance analysis (BIA) is a more accessible alternative. It sends a small electrical current through your body to estimate how much of your weight is muscle versus fat versus water. BIA devices are portable, inexpensive, and increasingly common in clinics. The results correlate well with DXA, but BIA tends to overestimate muscle mass slightly. Hydration status and body position also affect accuracy. For the most reliable reading, you should be standing or sitting for at least 20 minutes before the measurement, since body fluid shifts when you change position.
CT and MRI scans provide the most detailed view of individual muscles and can assess muscle quality (detecting fat that has infiltrated the muscle tissue). However, they’re expensive, time-consuming, and in the case of CT, involve significant radiation. These are reserved for research settings or high-risk specialty cases, not routine diagnosis.
Step 4: Grading Severity
Once sarcopenia is confirmed, performance-based tests determine how severe it is. Severity matters because it predicts your risk of falls, disability, hospitalization, and death.
Gait speed is the simplest severity measure. You walk a short distance (typically 4 to 6 meters) at your normal pace, and the time is converted to meters per second. A gait speed below 0.8 m/s is the established cut-point for sarcopenia-related impairment. Speeds below 0.6 m/s signal high risk of adverse outcomes, while speeds above 1.0 m/s are associated with low risk.
The Short Physical Performance Battery (SPPB) combines three timed tasks: a standing balance test (holding progressively harder stances for 10 seconds each), five chair stands, and a 4-meter walk. Scores range from 0 to 12, with higher scores indicating better function. Scores of 0 to 3 represent very low performance, 4 to 6 is low, 7 to 9 is moderate, and 10 to 12 is high. For sarcopenia severity grading, a score of 8 or below generally indicates impaired physical performance.
The Timed Up and Go (TUG) test measures how long it takes you to stand up from a chair, walk 3 meters, turn around, walk back, and sit down again. A time of roughly 11 seconds or more has been shown to predict sarcopenia with good accuracy (88.7% specificity in one study of hospitalized older adults). The 400-meter walk test is another option, particularly useful for detecting limitations in endurance rather than just short-burst function.
Differences Between European and Asian Guidelines
The two most influential diagnostic frameworks are the EWGSOP2 (used primarily in Europe and North America) and the AWGS 2019 (designed for Asian populations). Both follow a similar screening-to-confirmation logic, but they differ in specific thresholds and practical workflow.
The AWGS 2019 guidelines propose separate algorithms for community and hospital settings, both beginning with either calf circumference, SARC-F, or SARC-CalF screening. The strength and muscle mass cut-offs are calibrated to Asian body composition norms. For muscle mass, the AWGS uses DXA cut-offs of below 7.0 kg/m² for men and below 5.4 kg/m² for women, and BIA cut-offs of below 7.0 kg/m² for men and below 5.7 kg/m² for women.
These regional differences matter. Using European thresholds on an Asian population (or vice versa) can lead to under- or over-diagnosis. If you’re being evaluated, the guidelines most appropriate for your ethnic background and body size should guide the thresholds your provider uses.
What the Diagnosis Means Going Forward
Sarcopenia received its own medical disease code (ICD-10-CM M62.84) in 2016, which was a turning point in how the condition is treated by the healthcare system. It’s no longer considered just a normal part of aging. Having a formal code means the diagnosis can be documented in medical records, tracked over time, and potentially covered by insurance for treatment purposes.
The diagnosis itself falls into three tiers. “Probable sarcopenia” means low muscle strength was detected, even without imaging confirmation. “Confirmed sarcopenia” means both low strength and low muscle mass are documented. “Severe sarcopenia” adds poor physical performance on top of the other two. Each tier carries progressively higher risk of falls, fractures, loss of independence, and mortality, and each calls for progressively more aggressive intervention with resistance exercise and nutritional support.